Impacts of Tardive Dyskinesia (TD) Symptoms on Patients: Analysis of a TD-Specific Patient-Reported Outcome
Objective: To understand the impact of tardive dyskinesia (TD) symptoms on patients, confirm the appropriateness of the Tardive Dyskinesia Impact Scale (TDIS) as a patient-reported…Patterns of Improvement with Valbenazine in Patients with Tardive Dyskinesia
Objective: To characterize different patterns of improvement with valbenazine (VBZ) in patients with tardive dyskinesia (TD) using Abnormal Involuntary Movement Scale (AIMS) data from KINECT…Predictors of Persistence to Deutetrabenazine Among Patients With Tardive Dyskinesia (TD) and Huntington’s Disease (HD)
Objective: To identify real-world predictors of persistence to deutetrabenazine in patients with TD or HD. Background: Deutetrabenazine is FDA-approved to treat TD in adults and…Evaluation of the QTc prolongation risk of deutetrabenazine
Objective: To assess QTc prolongation risk of deutetrabenazine and its active metabolites by conducting exposure-QTc interval modeling, and to predict QTc prolongation in both CYP2D6…Risk of Tardive Dyskinesia in Patients with Tic Disorders: Preliminary Results
Objective: To determine the relative risk of tardive dyskinesia in patients with tic disorders by comparing three clinical populations: i) patients with tic disorders without…Comparison of Safety and Tolerability of Deutetrabenazine (DTBZ) During Titration and Maintenance in Patients With Tardive Dyskinesia (TD)
Objective: To compare safety of DTBZ in titration vs maintenance using data from two 12-wk placebo (PBO)-controlled studies (ARM-TD and AIM-TD) and an open-label extension…Real-World Deutetrabenazine Dosing Patterns in Patients With Huntington’s Disease or Tardive Dyskinesia
Objective: To evaluate real-world treatment patterns and adherence to deutetrabenazine (DTBZ) in patients with Huntington’s disease (HD) or tardive dyskinesia (TD). Background: DTBZ is a…The Impact of Antipsychotic Dose Reduction Within a Medicare Population
Objective: To analyze the burden of antipsychotic (AP) dose reduction in Medicare patients with schizophrenia (SZ). Background: Tardive dyskinesia (TD) develops in patients treated with…Deutetrabenazine Reduces Involuntary Movements in Patients Most Severely Impacted by Tardive Dyskinesia in a 3-year Open-Label Extension Trial
Objective: To evaluate the efficacy of deutetrabenazine (DTBZ) in reducing TD in the most severely impacted patients using data from an ongoing open-label extension (OLE)…Long-Term Treatment With Deutetrabenazine (DTBZ) Is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From the Completed, 3-year Open-Label Extension (OLE) Study
Objective: To evaluate long-term efficacy and safety of DTBZ in patients with TD by examining change from baseline in Abnormal Involuntary Movement Scale (AIMS) scores…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 8
- Next Page »